Orexin (OX)
Orexin-A and orexin-B (also known as hypocretin-1 and hypocretin-2, respectively) are neuropeptides that bind to the GPCRs (GPCR-A6 subfamily) orexin-1 (OX1) and orexin-2 (OX2). The orexin system has been implicated in the regulation of functions such as reward seeking, feeding behavior, locomotion and physical activity, and arousal from sleep and the sleep–wake cycle. Upon receptor activation, intracellular calcium levels increase. Orexin deficiency has been linked to narcoleptic symptoms such as sudden sleep attacks and cataplexy[1].
[1] Orexin Receptor Antagonism, a New Sleep-Enabling Paradigm: A Proof-of-Concept Clinical Trial. P. Hoever et al. Clin. Pharm. Ther. 2012, 91, 975-985.
| Axon ID | Name | Description | From price | |
|---|---|---|---|---|
| 2012 | EMPA | Orexin type 2 (OX2) receptor antagonist | €135.00 | |
| 3805 | MK-3697 | Potent and selective Orexin receptor antagonist | Inquire | |
| 2095 | SB 334867 | First selective orexin 1 (OX1) antagonist | €90.00 | |
| 2192 | SB 674042 | Nonpeptide OX1 selective antagonist with >100 fold selectivity over the OX2 receptor. | €99.00 | |
| 2744 | TCS1102 | Dual orexin (OX1/2) receptor antagonist | €90.00 | |